Essential thrombocythaemia in children: is a treatment needed?

Area of Science:

• Hematology
• Pediatric Oncology
• Internal Medicine

Background:

• Essential thrombocythaemia (ET) is a rare myeloproliferative neoplasm in children.
• Unlike adults, pediatric ET patients rarely experience thrombosis or hemorrhage.
• Accurate diagnosis is crucial to differentiate ET from other causes of thrombocytosis.

Purpose of the Study:

• To review the current understanding and management of ET in children.
• To provide guidance on diagnosis and treatment strategies for pediatric ET.

Main Methods:

• Literature review of published studies and anecdotal experiences on pediatric ET.
• Analysis of diagnostic challenges and therapeutic options.

Main Results:

• Diagnosis of ET in children can be challenging.
• A watch-and-wait approach is suitable for asymptomatic children.
• Low-dose aspirin can mitigate microvascular disturbances.

Conclusions:

• Anagrelide or interferons (IFNs) are potential first-line treatments.
• Hydroxyurea is a viable second-line option.
• Anagrelide may become a preferred treatment if its non-leukemogenic potential is established.